Veeva Systems has announced a collaboration with UCB, whereby the pharma company will adopt Veeva's ePRO and eConsent solutions, to provide a patient-centric, digital experience to study participants.
Veeva ePRO offers the design, management, and completion of electronic patient-reported outcomes (ePRO) with data flow among sponsors, sites, and patients. Veeva eConsent offers the set-up, completion, and review of consent for patients, sites, and study teams. Both applications are available to patients through MyVeeva for Patients, which provides access for participants clinical trial activities, scheduling, and communications. Veeva ePRO and Veeva eConsent are part of Veeva Vault Clinical Suite, a set of integrated capabilities for both clinical operations and clinical data management.
UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials. (May 23, 2023). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.